Z-DNA-binding protein 1 Antibodies

Z-DNA-binding protein 1 (Zbp1)

Participates in the detection by the host's innate immune system of DNA from viral, bacterial or even host origin. Plays a role in host defense against germs and pathogens.

Referred to as a cytoplasmic DNA sensor that, when activated, induces the recruitment of TBK1 and IRF3 to its C-terminal region and activates the downstream interferon regulatory factor (IRF) and NF-kappa B transcription factors, leading to type-I interferon production. ZBP1-induced NF-kappaB activation probably includes the recruitment of the RHIM containing kinases RIPK1 and RIPK3.

Gene Information

Mouse
Gene Name:	Zbp1
Uniprot:	Q9QY24
Entrez:	58203

Family

Belongs to:
No superfamily

Alternative Names

C20orf183; chromosome 20 open reading frame 183; DAI; DLM1; DLM-1; DLM1dJ718J7.3; DNA-dependent activator of interferon regulatory factors; DNA-dependent activator of IRFs; Tumor stroma and activated macrophage protein DLM-1; ZBP1 Z-DNA binding protein 1; ZBP1; Z-DNA binding protein 1; Z-DNA-binding protein 1

Molecular Weight

Mass (kDA):
44.331 kDA

Genomic Context

Mouse
Location:	2|2 H3
Sequence:	2;

Tissue Specificity

Expressed in lung, spleen and liver. Lower levels were seen in heart, kidney and testis. Expression is greatly up-regulated in tumor stromal cells and activated macrophages.

Diseases

• Innate Immune Response
• Neoplasms
• Inflammation
• Neoplasm Metastasis
• Melanoma
• Malignant Neoplasms
• Carcinoma
• Autoimmune Diseases
• Infective Disorder
• Virus Diseases
• Autoimmune Reaction
• Cytomegalovirus Infections
• Mammary Neoplasms

• Adenocarcinoma
• Cell Invasion
• Tissue Adhesions
• Sting Injury
• Malignant Neoplasm Of Breast
• Neoplasm Invasiveness
• Immunologic Deficiency Syndromes

Pathways

• Localization
• Translation
• Transport
• Immune Response
• Innate Immune Response
• Cell Motility
• Mrna Transport
• Cell Migration
• Nuclear Export
• Rna Localization
• Cell Death
• Pathogenesis
• Secretion

• Cell Adhesion
• Regulation Of Gene Expression
• Chemotaxis
• Axon Guidance
• Adaptive Immune Response
• Virulence
• Clustering Of Voltage-gated Calcium Channels

PTMs

• Phosphorylation

• Methylation

• Demethylation

For details, visit:
bosterbio.com/bosterbio-gene-info-cards/Zbp1

Best Uses Of The ZBP1 Marker

The antibodies created for the detection of Z-DNA-binding protein 1 (ZBP1) in many biological tests are monoclonal and polyclonal. The antibody reacts with ZBP1 in various samples, ranging from bacteria and viruses to tissues and cells. Boster Bio develops these antibodies with rabbit and mouse models. The defense of the host against pathogens is a key function of the ZBP1.

ELISA assay for ZBP1 in mice. ZBP1

The ELISA test for mouse ZBP1 also known as EZB-1, uses an enzyme-linked immunosorbent. The ZBD attaches the endogenous DNA to the enzyme. Infected cells also experience an IFN response. This makes the test extremely sensitive and precise test for detecting mouse ZBP1.

The serum concentration is used to determine the enzyme's activities. A high concentration of ZBP1 can cause necrosis in cells infected with ZBP1. Endogenous nucleic acids interact with the enzyme at high levels. It is possible to prevent the development of cancer by high levels of ZBP1 in blood. Therefore, the ELISA test for ZBP1 in mice is a great instrument to study cell death.

To carry out the ELISA test for mouse ZBP1 immortalized MEFs that were stably expression of FLAG-ZBP1 were injected with the IAV. The cytoplasmic and nuclear portions of infected cells were separated at the appropriate times. The PCR procedure was employed to aid in identification of PA segment-derived DVGRNA RNA. Infection-free cells showed a reduction in cell death. Infection-induced cell death was prevented in Zbp1-/ mice.

The ELISA assay for mouse ZBP1, which can detect the cellular RNA as well as mRNA, is a great tool for research. It can detect mRNA (rRNA) and DNA. It also assists in the diagnosis of human diseases like cancer. The ELISA test is the most effective way for you to find out if your body is expressing the protein you're seeking.

ELISA test for mouse ZBP1. Diagnostics by molecular analysis Diagnostics Molecular: An ELISA test for mouse ZBP1 which can detect levels of mRNA in serum as well as blood and urine. If your test detects the expression of mRNA the result will be indicated. If you are suffering from infection by microbes, you must know how much mouse ZBP1 is in your blood. You can also measure the levels of this protein in your body by comparing your samples with an untreated group.

ELISA assay for mouse ZBP1, also known as EZB-1 is a great tool for viral analysis. This enzyme binds viral DNA and mRNA to infected cells. It also detects viral DNA inside a cell. The test for mouse ZBP1 is simple and sensitive. Once you have the mRNA/virus you can run the analysis.

This enzyme was identified as a key factor in the severe COVID-19 disease. Its function in IFN therapy response is unknown. ZBP1 is now believed as one of the most important cytosolic sensors during infection with B-coronavirus and MHV. It is responsible for the death of inflammatory cell. Infected mice with ZBP1 showed less susceptibility to COVID-19 infection. This suggests that the host must have an effective defense against IAV.

The ELISA assay for mouse ZBP1 was previously known as EZB-1 was developed in collaboration with University of California, San Diego. Its method involved immortalizing Zbp1cells that had been infected with IAV. The cells were then infiltrated into PBS and then transferred to a fractionation buffer containing nucleic extracts. The nuclear pellets were then collected for analysis after four to five lysis steps.

Research Spotlight on PD-1 expression regulation

In the EHR and spotlight cohorts, 32% and 38% of patients received ICIs for a median of 7.3 months in each. Patients who qualified for ICIs were also treated with chemotherapy for approximately 6 months. However, in the spotlight cohorts, 30% to 40% of patients received further treatments such as a third-line PD-1 inhibitor. This study offers important data for clinicians as well as researchers as well.

This study investigated the expression of PD-1 during metastatic GEPNET. The study involved 32 patients with metastatic GEPNET that were diagnosed between June 2011 and September 2014. The patients were screened for their age and gender. The tumor grade was determined by using the 2010 WHO classification. The researchers conclude that PD-L1 expression is associated with better prognostic and predictive outcomes for GEP-NET metastatically.

PD-L1 expression was linked to numerous clinical variables. It was also associated with disease outcomes like response rates and disease control. The time period between the start of treatment until the death or progression of disease was measured as total survival and the survival that is not affected by progression. The researchers utilized descriptive statistics, such as medians, proportions, as well as confidence intervals, to analyze the data. Kaplan-Meier analyses were employed to calculate confidence intervals for time-to-event variables.

Recent research in Oncogene discovered that SIP1 regulates the expression of PD-1 in human epithelial tumor cells. This is the first study to show a correlation between SIP1 & the PD-L1 gene. This underscores the significance of these genes in regulating PD1 expression in cancer. These results are important in the treatment of cancer. However it is necessary to conduct more research to determine which treatments are most effective in decreasing the risk of developing the cancer and prolonging the survival.

An immunosuppressive microenvironment can be created by tumor cells that are PD-L1 levels that are upregulated. This can cause tumor progression and metastasis. The PD-1 mechanism can be controlled to provide anti-tumor therapy. It is a crucial component in the development of new PD-1-based anticancer drugs. It also facilitates polarized cell movement via its mTORC2 signal. In addition, it is involved in the regulation of RhoA.

As PD-L1 has been approved for clinical trials, scientists are investigating the mechanisms that regulate its expression. PTMs of PD-L1 are usually therapeutic targets and a better understanding of the regulation of this protein can improve the efficacy of immuno-targeting treatments. A better understanding of PD1's expression could increase the effectiveness of immunotherapies, and enable better selection of patients.

Clinical applications

The discovery of the ZBP1 gene and its pro-death interactions has opened the way to new treatment options for cancer. The ability to fight disease with ZBP1 is dependent on its interaction with ADAR1 an enzyme that regulates cell death. The interaction between ZBP1 and ADAR1 determines the survival of tumor cells. The study also showed that ZBP1 and TRIF are controlled by each other.

ZBP1 acts as a restriction factor for HSV-1 in murine primary astrocytes. ZBP1-mediated activation of cell death results in a reduction in viral particles releasing into the bloodstream and necroptosis. ZBP1 can improve host protection by inhibiting replication of DNA viruses. It is an attractive therapeutic target for HSV Encephalitis. This article provides a short overview of its clinical uses.

Although ZBP1's role in glia remains unclear, it does contribute to the production of pro-inflammatory mediators in response to HSV-1 infection. It is unclear however, if ZBP1 is a vital component of the cross-talk between microglia and RPE. This research is significant however further research is needed to determine its clinical relevance. In the meantime, ZBP1 is a promising marker for detecting HSV-induced neurodegeneration.

In mice, the oxidatively damaged mtDNA gets transferred to the cytoplasm where it permanently binds the ZBP1 receptor. This is related to inflammation and progressive vision loss. It is also apparent that ZBP1 activation enhances the expression of proinflammatory markers in RPE cells. This gene has significant clinical implications in the treatment of disease and detection. The clinical applications for this gene are numerous.

The ZBP1 gene is involved in various disease processes, including immune system disorders and inflammation. Inflammatory processes caused by viruses include necroptosis. Inflammation-mediated necrosis is associated with an increased production of IL-1b. The increased levels of ZBP1 are usually associated with inflammation. ZBP1 may also play a important role in the prevention of inflammation-induced cell death.

ZBP1 is a key player in viral infection and inhibits the growth of WNV. In the mouse model of WNV disease, ZBP1-/ mice showed reduced WNV and ZIKV. ZBP1 is crucial for survival in humans. This study suggests that ZBP1 plays a significant role for preventing and treating diseases. There are currently no genetic markers for the ZBP1 gene.

Previous research had shown that astrocytes that produce high quantities of ZBP1 are invulnerable to HSV infection. This immune system's cellular response is decreased in mice deficient in ZBP1 and astrocytes release small amounts of IFN-1b. Additionally, studies have shown that ZBP1 deficiency doesn't hinder the production of essential inflammation-related cytokines like IL-6.

A ZBP1 deficiency decreased the expression of inflammatory mRNA when caused by infection with LPS/5z7. ZBP1 regulates different levels of TRIF signaling. Therefore, it is an ideal candidate for disease prevention and treatment. The deficiency could also affect the production of an inflammatory gene mRNA. The study showed that ZBP1 deficiency lowered the expression of CASP1, an inflammation protein, further confirming its role as an inhibitor of inflammation.